The immune response against transplanted allografts is one of the most potent reactions mounted by the immune system. The acute rejection response has been attributed to donor dendritic cells (DCs), which migrate to recipient lymphoid tissues and directly activate alloreactive T cells against donor MHC molecules. Here, using a murine heart transplant model, we determined that only a small number of donor DCs reach lymphoid tissues and investigated how this limited population of donor DCs efficiently initiates the alloreactive T cell response that causes acute rejection. In our mouse model, efficient passage of donor MHC molecules to recipient conventional DCs (cDCs) was dependent on the transfer of extracellular vesicles (EVs) from donor DCs that migrated from the graft to lymphoid tissues. These EVs shared characteristics with exosomes and were internalized or remained attached to the recipient cDCs. Recipient cDCs that acquired exosomes became activated and triggered full activation of alloreactive T cells. Depletion of recipient cDCs after cardiac transplantation drastically decreased presentation of donor MHC molecules to directly alloreactive T cells and delayed graft rejection in mice. These findings support a key role for transfer of donor EVs in the generation of allograft-targeting immune responses and suggest that interrupting this process has potential to dampen the immune response to allografts.
Introduction
In the absence of immunosuppression, the strong adaptive immune response against organ allografts is the main impediment to successful transplantation. The potency of the adaptive immune response to alloantigens on the graft is attributed to migration of donor-derived professional antigen-presenting cells (APCs) as dendritic cells (DCs) to the recipient lymphoid tissues, where the donor APCs trigger the activation of directly allospecific T cells against donor MHC molecules (1, 2). Nevertheless, the idea that donor leukocytes migrated from transplanted organs present by themselves intact MHC molecules to directly alloreactive T cells in situ in graft-draining lymphoid tissues has been questioned in recent years (3) (4) (5) (6) (7) . There is indirect evidence in murine models that donor DCs mobilized from organ allografts home in recipient lymphoid tissues in relatively low numbers (2) , are shortlived because they are targets for recipient NK cells and cytotoxic T lymphocytes (8) (9) (10) , and do not interact efficiently with directly alloreactive T cells (11) . Nevertheless, the donor DCs mobilized from mouse heart allografts to lymphoid tissues of naive recipients, even at what seems to be extremely low DC/T cell ratios, are able to elicit the potent antidonor response that acutely rejects the graft (2) . By contrast, the allostimulatory ability of fully mature DCs is barely detectable in mixed leukocyte cultures below an APC/T cell ratio of 1:100 (12) . These apparently contradictory findings have raised the question of how, in some transplantation models, the limited number of graft-derived DCs that home in graft-draining lymphoid tissues activates so efficiently directly allospecific T cells. This is particularly intriguing in nonsensitized recipients, where naive T cells against alloantigens are present in relatively lower percentages and have a higher activation threshold than the allo-or cross-reactive memory T cells found in presensitized recipients.
Here, we demonstrated that the relatively few donor DCs mobilized from heart allografts to lymphoid tissues of naive recipients amplify their ability to stimulate directly alloreactive T cells by transferring clusters of extracellular vesicles (EVs), with characteristics of exosomes and bearing functional donor MHC molecules and APC-activating signals, to a higher number of recipient conventional DCs (cDCs). Exosomes are 70-to 120-nm EVs originated in the endocytic compartment of living cells, which have been shown to transfer proteins and RNAs between cells (13) (14) (15) (16) . We found that after cardiac transplantation, the donor-derived exosomes remain attached to or are internalized by recipient cDCs in graft-draining lymphoid tissues, but they did not fuse with the plasma membrane of the acceptor APCs. Uptake of donorderived exosomes, unlike interaction with other types of donor EVs, enhanced the ability of the acceptor (recipient) DCs to stimulate allospecific T cells. In accordance with the finding that recipient DCs present donor MHC molecules acquired through EVs to directly alloreactive T cells, depletion of recipient DCs abrogated activation of directly alloreactive T cells, and delayed allograft rejection. Our findings define a new role for exosome transfer, as a mechanism of spreading donor MHC molecules and APC-activating signals from a limited number of graft-derived migrating DCs
The immune response against transplanted allografts is one of the most potent reactions mounted by the immune system. The acute rejection response has been attributed to donor dendritic cells (DCs), which migrate to recipient lymphoid tissues and directly activate alloreactive T cells against donor MHC molecules. Here, using a murine heart transplant model, we determined that only a small number of donor DCs reach lymphoid tissues and investigated how this limited population of donor DCs efficiently initiates the alloreactive T cell response that causes acute rejection. In our mouse model, efficient passage of donor MHC molecules to recipient conventional DCs (cDCs) was dependent on the transfer of extracellular vesicles (EVs) from donor DCs that migrated from the graft to lymphoid tissues. These EVs shared characteristics with exosomes and were internalized or remained attached to the recipient cDCs. Recipient cDCs that acquired exosomes became activated and triggered full activation of alloreactive T cells. Depletion of recipient cDCs after cardiac transplantation drastically decreased presentation of donor MHC molecules to directly alloreactive T cells and delayed graft rejection in mice. These findings support a key role for transfer of donor EVs in the generation of allograft-targeting immune responses and suggest that interrupting this process has potential to dampen the immune response to allografts. Figure 1A) . When quantified by PCR, a maximum of 1,127 to a higher number of recipient APCs in graft-draining lymphoid tissues. They also unveil at the ultrastructural level and in vivo the mechanism of cross-dressing of recipient cDCs with donor MHC molecules after transplantation and the primary role that this pathway has in allograft rejection.
EVs, including exosomes, are emerging as potential biomarkers and therapeutic agents in transplantation medicine (17) . Although increasing evidence suggests that EVs may have relevant biological functions, the information in vivo is still very limited (18) . Our results reveal in vivo a rather unexpected role for donor-derived exosomes in the pathophysiology of transplant rejection, and provide an explanation for the potency of alloimmunity. A deeper understanding analysis ( Figure 1, C and D) . Surprisingly, FACS analysis revealed that the quantity of recipient splenic APCs carrying donor MHC was approximately 100-fold higher than the number of donor DCs homed to the spleen ( Figure 1 , B and D, and Supplemental Figure  2 ). Donor MHC molecules were found mainly on recipient cDCs ( Figure 1D ). Thus, after transplantation of fully mismatched cardiac grafts, donor DCs were detected in limited numbers in draining lymphoid tissues, whereas a higher number of recipient cDCs carried donor MHC molecules on the cell surface.
Graft DCs transfer EVs with functional MHC antigens to recipient APCs in lymphoid tissues. Next, we investigated the mechanism(s) ± 372 donor cells was detected in the spleen on postoperative day (POD) 1 ( Figure 1B ). In the retroperitoneal and mediastinal lymph nodes of the recipients, donor DCs were also difficult to detect by microscopy, and were undetectable by quantitative genomic PCR (detection limit of 1 BALB/c cell in 10 6 B6 cells), during the first 7 PODs (Supplemental Figure 1 , A-C; supplemental material available online with this article; doi:10.1172/JCI84577DS1). Therefore, we postulated that the donor leukocytes that reach the graftdraining lymphoid tissues must transfer via cross-dressing donor MHC to a high number of recipient APCs. Indeed, we detected donor MHC on recipient splenic cDCs by microscopy and FACS Figure 5A ). BALB/c cDCs failed to transfer MHC when separated from B6 cDCs by 0.4-μm-pore transwells ( Figure 5B), which confirms that MHC transfer occurred via EV clusters that, because of their hydrodynamic size (i.e., Stokes radius), did not cross the filter pores. Thus, in the context of a passive Brownian-like diffusion, EV clustering might play a key role in the lack of migration of the vesicles through a 0.4-μm pore.
B6 cDCs that acquired BALB/c EVs in cDC cocultures activated directly alloreactive 2C T cells (Supplemental Figure 5) . Controls demonstrated that 2C T cell stimulation was not due to carryover of BALB/c cDCs to the FACS-sorted B6 cDCs crossdressed with BALB/c EVs (Supplemental Figure 5) Figure 2 ) bearing donor H2K d were FACS-sorted, and examined by electron microscopy (EM) (Figure 2A ). We found that donor MHC was transferred via EVs attached to recipient cDCs ( Figure 2B ). The EVs were 75.7 ± 32.1 nm in diameter and positive for the exosomeassociated tetraspanins CD9 and CD63 (Figure 2 , B-D). Exosomes are EVs of endocytic origin released by fusion of multivesicular bodies (MVBs) with the cell membrane (13-16). We did not find donor-derived EVs fusing with recipient cDCs, or donor MHC molecules expressed directly on the recipient cDC surface ( Figure  2B ). The donor-derived EVs did not incorporate into the plasma membrane of the acceptor (B6) cDCs, but remained attached to it, partially preserving its vesicular structure. Importantly, the lack of expression as an integral membrane protein of donor H2D d and IA d molecules on the surface of those cDCs cross-dressed with the EVs confirmed the recipient (B6) origin of the acceptor cDCs (Figure 2B ). FACS-sorted recipient (B6) splenic cDCs carrying donor (BALB/c) MHC activated naive 2C CD8 T cells, which are directly alloreactive to BALB/c H2L d ( Figure 3 , A-C). Thus, recipient cDCs cross-dressed in vivo with EVs carrying donor MHC molecules can prime directly alloreactive CD8 T cells.
To gain further insight into the MHC antigen cross-dressing process, we investigated the mechanism of MHC transfer between cDCs through EVs in cocultures of BALB/c cDCs (CFSE-labeled) To identify the type(s) of EVs that transfer MHC, cocultures of BALB/c and B6 DCs were done using donor (BALB/c) DCs pretreated with Rab27a siRNA to inhibit exosome release (19) , or in the presence of imipramine or DEVD, which decrease release of microvesicles (MVs) or apoptotic EVs, respectively (20) (21) (22) transfer of RFP to YFP + cDCs after injection of control BALB/c BMDCs expressing cytosolic RFP (Supplemental Video 8), which should be able to transfer MVs or apoptotic blebs containing cytosolic RFP within the EVs. These results indicate that migrating DCs transfer clusters of exosomes to cDCs in lymphoid organs in vivo, and that such EVs remain attached to the cell surface or are internalized by the acceptor DCs.
Acquisition of EVs released by graft migrating DCs promotes recipient APC activation. We found that recipient splenic cDCs upregulate activation markers after transplantation of BALB/c hearts in B6 mice ( Figure 7A ). Therefore, we investigated whether passage of EVs promotes DC activation. Following injection of CD63-RFP BALB/c BMDCs in CD11c-YFP B6 mice, those splenic cDCs that acquired RFP-tagged exosomes expressed higher amounts of endogenous MHC class II (IA b ), CD40, CD80, and CD86, but similar levels of the regulatory molecule PD-L1, in comparison with splenic cDCs without RFP ( Figure 7B ). We investigated whether this phenomenon was due to preferential uptake of the exosomes by already mature cDCs, or to exosome-induced maturation of Figure 8D ). Addition of immature BALB/c exosomes or MVs released by BALB/c mature BMDCs had little or no effect ( Figure 8D ). The increase of surface IA b content on B6 BMDCs required exposure to intact exosomes, since the effect disappeared when the EVs were disrupted by repetitive freezing and thawing ( Figure 8D ). Mature BALB/c exosomes also augmented, in a dose-dependent manner, expression of CD40, CD80, and CD86 (but not PD-L1) ( Figure 9A ), and the ability to stimulate third-party naive T cells in acceptor B6 BMDCs (Figure ras ( Figure 10B ). In both cases, the few donor DCs detected were located within or next to splenic T cell areas ( Figure 10C ). Thus, the method used for depletion of recipient cDCs did not interfere with the ability of graft-derived cDCs to migrate to the spleen or to home to T cell areas. BALB/c hearts transplanted in DC-depleted CD11c-DTR-B6 chimeras exhibited less damage and inflammation than BALB/c grafts from controls (Supplemental Figure 10) . As expected, the frequency of T cells against donor peptides presented by recipient cDCs ( Figure 10D ) and the titer of anti-donor antibodies (Abs) in serum ( Figure 10E ) (both dependent on recipient APCs) were similar to those in naive animals. Importantly, splenic T cells from cDC-depleted recipients did not respond against donor intact MHC molecules ( Figure 10D ), which indicates that recipient cDCs were necessary for sensitization of directly alloreactive T cells. The results were not due to DT-induced depletion of CD11c + T cells (Supplemental Figure 11) or splenic CD11c + macrophages (Supplemental Figure 12) .
Transfer of donor MHC molecules in an orthotopic transplant model. We investigated whether transfer of donor MHC molecules through passage of exosome clusters also occurs in an orthotopic 9B). These results indicate that exosomes released by mature DCs promote the maturation of acceptor DCs.
Recipient cDCs present acquired donor MHC molecules to directly alloreactive T cells. Since cDCs acquire donor MHC through EVs, we evaluated the role of recipient cDCs in priming directly alloreactive T cells. BALB/c hearts were transplanted in CD11c-diphtheria toxin receptor (CD11c-DTR) B6 BM chimeras, where DT injection depletes recipient cDCs. Control CD11c-DTR-B6 chimeras not exposed to DT rejected BALB/c heart grafts as rapidly as WT B6 recipients ( Figure 10A ). In contrast, survival of BALB/c cardiac grafts was significantly prolonged in CD11c-DTR-B6 BM chimeras depleted of recipient cDCs by DT injection ( Figure 10A ). This was not due to nonspecific effects of DT, since control DT-injected WT B6 BM chimeras rejected BALB/c hearts ( Figure 10A ) as rapidly as untreated WT B6 recipients (not shown). The increased survival of the BALB/c grafts in DT-treated CD11c-DTR-B6 BM chimeras was not due to impaired homing of donor DCs to spleens depleted of recipient cDCs. Indeed, similar numbers of donor migrating DCs (CD11c + IA d hi ) were detected by microscopy on PODs 1 and 3 in spleens of DT-treated CD11c-DTR-B6 BM chimeras and control DT-injected WT B6 BM chime- (12) . It is unlikely that these differences could be explained only by the 3D structure of the lymphoid tissue or mobility of naive T cells in vivo. Therefore, we investigated in this model the mechanism(s) by which the relatively few donor passenger DCs that reach the graftdraining lymphoid tissues prime so efficiently directly alloreactive T cells. We first noticed that although graft-derived DCs were detected at very low numbers in draining lymphoid tissues, most of the donor MHC molecules were found on clusters of EVs bound to recipient cDCs. Similar results were found in a fully mismatched orthotopic nonvascularized skin transplant model in mice.
Next, we investigated the origin of the EV-associated donor MHC molecules bound to the recipient cDCs in the draining lymphoid tissues. A possible explanation is that the graft sheds soluble MHC molecules into circulation, which are trapped by secondary lymphoid tissues. Interestingly, since its description in the 1980s (25, 26) , soluble MHC molecules were shown to be associated with membrane fragments, which later were characterized as EVs (27) . It is still uncertain whether systemic release of MHC molecules -likely through EVs -by parenchymal and transplant model of skin allografts. Following bilateral transplantation of BALB/c (H2 d , CD45.2) skin on the back of B6 (H2 b , CD45.1) mice, we were unable to detect by FACS donor migrating cDCs in the recipient spleen ( Figure 11A ) and graft-draining lymph nodes (i.e., axillary and inguinal). This agrees with previous studies done in fully mismatched skin transplant models in mice (8, 23) . During the first week after transplantation, however, a percentage of the recipient splenic cDCs acquired donor MHC class I (H2K d + H2D d ) and class II (IA d ) molecules ( Figure 11 , A and B). Both CD8α + and CD8α -cDCs were cross-dressed with donor MHC molecules ( Figure 11A ). The content of donor MHC antigen per DC and the percentages of recipient cDCs bearing donor MHC molecules increased along with time after surgery ( Figure 11B ). Passage of donor MHC molecules to recipient cDCs was not detected in controls grafted with syngeneic skin ( Figure  11B ). By ImageStream technology (EMD Millipore), the donor H2K d /H2D
d and IA d molecules were detected in spots on the recipient cDCs ( Figure 11C ). The punctate areas containing donor MHC molecules coexpressed the exosome marker CD63 ( Figure  11C ), which indicates they represent clusters of donor-derived exosomes bound to the recipient cDCs. A third possibility is the one described in this study, in which donor migrating DCs first reach the recipient lymphoid tissues and then transfer EVs carrying donor MHC and APC-activating signals to a higher number of recipient cDCs (28) .
Previous studies have shown that leukocytes transfer MHC via mechanisms that have been termed cross-dressing (29, 30) , trogocytosis (31), or cell nibbling (32) , depending on the model and type of cell involved. In the transplantation field, Lechler and colleagues originally described cross-dressing of DCs with allogeneic MHC molecules as the basis of what they termed the semidirect pathway of allorecognition (33) . Since then, others have detected in mouse models the presence of donor MHC molecules on recipient APCs after heart and kidney transplantation, and even the reversed passage of host MHC molecules to donor nonmigrating stromal cells of cardiac allografts is sufficient to prime directly allospecific T cells in graft-draining lymphoid organs. Interestingly, in the fully mismatched nonvascularized skin transplant model, we detected recipient cDCs carrying donor MHC molecules together with the exosome marker CD63 on the cell surface, but, unlike in the heart transplant model, we did not find donor DCs in the graft-draining lymphoid tissues. This finding opens the following 2 possibilities in the skin transplant model: (a) that donor exosomes are released within the graft-draining lymphoid tissue by donor migrating DCs that die rapidly after their arrival; or (b) that donor exosomes are released systemically by nonmigrating cells of the graft, or by donor DCs before leaving or trapped within the allograft. A potential problem with this latter idea is that once released systemically, the EVs passively traffic through the bloodstream and other bodily fluids, where they become dispersed, and from where they are rapidly captured for degradation by macrophages throughout the body (15) . Actually, systemic dilution and rapid clearance of circulating EVs by phagocytes are drawbacks for the therapeutic application of systemically administered EVs (15). cDC surface. EVs carry on the surface adhesion molecules and their ligands that could stabilize the EV cluster.
Transfer of RFP-tagged exosomes from BALB/c migrating BMDCs to lymph node-or spleen-resident B6 YFP + cDCs occurred within minutes. We also demonstrated that the transferred exosomes were retained on the acceptor cDC for hours, or internalized. Transfer of clusters of exosomes -and potentially other types of donor-derived EVs -likely facilitates organization of the immunological synapse (much bigger in diameter than an individual exosome), and provides sufficient density of donor MHC molecules to promote activation of directly alloreactive naive T cells.
Unlike other types of EVs, exosomes released by activated DCs promoted activation of acceptor cDCs in our model, which depended on the dose of exosomes transferred and the preservation of the vesicular structure. Previous studies have shown that exosomes released by mast cells (45) , red blood cells (46) , or pathogen-infected macrophages (47) promote activation of DCs and monocytes. Interestingly, exosomes released by mature DCs are enriched in miR-155 and contain heat-shock proteins, both inducers of DC activation (48, 49) .
If donor migrating cDCs transfer through EVs donor MHC molecules and APC-activating signals to recipient cDCs, depletion of the latter cells should interfere with priming of directly alloreactive T cells. Accordingly, in the absence of recipient cDCs, T cell priming against donor MHC molecules was drastically impaired, and therefore cardiac allograft rejection was delayed. This confirms that in our model (nonsensitized recipients), the relatively few donor DCs homed in the spleen were not sufficient to prime directly alloreactive naive T cells. These donor DCs rather function as antigen-transporting cells, spreading donor MHC and APC-activating signals to a higher number of recipient cDCs in lymphoid tissues.
Certain microbial components, allergens, and model or tumor antigens are sorted into exosomes released by APCs, including DCs (15) . Although our findings are in transplantation, transfer of preformed self MHC:peptide complexes via exosomes or other EVs from migrating DCs to a higher number of lymphoid tissue-resident cDCs could also enhance T cell stimulation during microbial infections, allergies, or vaccinations. In this regard, Smyth et al. have elegantly shown that virally infected migrating cDCs transfer functional MHC class I:peptide complexes to splenic cDCs, which then primed CD8 T cells against virus-encoded antigens (30, 50) . Cross-dressed DCs are also relevant for expansion of memory CD8 T cells after viral infections (29) . DCs designed for vaccination transfer in vitro MHC class I:peptides via exosomes to other DCs for efficient CD8 T cell priming (51) . Thus, amplification of the T cell response via passage of exosomes between migrating DCs and cDCs of lymphoid tissues is likely a generalized phenomenon not restricted to transplant immunity.
In summary, our study has identified dissemination within graft-draining lymph nodes of donor-derived exosomes bearing MHC molecules and APC-activating signals, as a key component of the effectiveness of the response against non-self MHC molecules in organ transplantation. We demonstrated that this is a general phenomenon that occurs in vascularized (heart) and nonvascularized (skin) transplant models. Our findings do not exclude the potential contribution of other types of donor-derived EVs in DCs after BM transplantation (34) (35) (36) . By the semidirect pathway, an individual DC from the recipient is able to present both (a) donor intact MHC molecules to trigger activation of directly alloreactive naive CD8 T cells and (b) donor-derived peptides in recipient (self) MHC molecules to stimulate indirectly alloreactive CD4 T cells required to provide linked help to the APC for stimulation of the naive CD8 T cells (37) (38) (39) . The semidirect pathway explains how indirect-pathway T cells not only stimulate but also cross-regulate the function of direct-pathway T cells through the same recipient APC (40, 41) . The results presented here unveil at the ultrastructural level and in vivo the mechanism of transfer of MHC molecules between donor and recipient cDCs, which is the basis of the semidirect pathway. Furthermore, they demonstrate that spreading of clusters of exosomes bearing donor MHC molecules plus APC-activating signals increases the probability that the relatively few donor DCs migrated from mouse cardiac allografts will prime effectively directly alloreactive T cells at the extremely low DC/T cell ratios detected in the graft-draining lymphoid tissues.
Interestingly, until now the mechanism(s) behind passage of MHC between leukocytes in vivo has not been fully elucidated. Exchange (or unidirectional passage) of fragments of plasma membrane between donor and acceptor cells has been proposed (42) . However, transfer or exchange of patches of plasma membrane between leukocytes has not been confirmed at the ultrastructural level. A more plausible alternative is that leukocytes transfer MHC through EVs, which differ in biogenesis, size, and molecular composition. MVs and apoptotic cell blebs range between 0.2 and 1 μm in size and are shed from the surface membrane of living and dying cells, respectively (16) . In contrast, exosomes are smaller vesicles (30-120 nm) of endocytic origin generated in late endosomes/MVBs, and secreted when MVBs fuse with the plasma membrane (16) .
An interesting finding in our model is that transfer of MHC between cDCs was minimal when cells were separated with 0.4-μm-pore transwells. In general, the conclusion of such a result is that MHC transfer occurs through capture of plasma membrane patches from donor cells, instead of transfer of free floating EVs. However, our results by EM showed that the donor MHC molecules were transferred via clusters of clumped small EVs that, because of their size and Brownian motion, were unable to pass through the 0.4-μm pores. Besides, transfer of such EV clusters may also require cell-to-cell contact.
The composition of EVs depends on the lineage and activation of the parent cell. EVs released by mature DCs are enriched in MHC, adhesion, and T cell costimulatory molecules (28, 43) . Numerous studies have shown that APCs acquire MHC molecules by binding APC-derived exosomes added as free EVs to the culture medium (28, 29, 43, 44) . These results have led to the idea that APCs always capture exosomes and other EVs as free-floating individual vesicles through mechanisms that do not require intercellular contact. In contrast, our work demonstrates that donor migrating DCs transfer MHC molecules by passing clusters of small EVs -instead of individual EVs -to recipient cDCs. Release of small EVs to the confined area of the intercellular space limits dispersion of the EVs by Brownian motion, allowing retention of the transferred EVs within a confined area of the acceptor jci. Abs, fixed in PFA, and analyzed by FACS. Confocal microscopy. BALB/c DCs were generated from BM precursor cells cultured in RPMI 1640 supplemented with 10% FCS, GM-CSF (1,000 U/ml), and IL-4 (500 U/ml). in CD11c-YFP B6 mice. Before injection, CD11c + BMDC purity was ≥ 95% and cell viability ≥ 98% (by FACS). After BMDC injection (16 hours), the ipsilateral popliteal lymph nodes or the spleens were harvested. The spleens were cut into 400-μm-thick explants with a vibratome. The lymph nodes and spleen explants were embedded in 3% low-melting-temperature agarose and mounted in a custom-designed closed chamber perfused with medium bubbled with 95% O 2 /5% CO 2 , at 37°C. Samples were imaged with a Nikon Eclipse Ti confocal system or with a Nikon A1MP + multiphoton confocal microscope. Time-lapse Purification of EVs. MVs and exosomes were purified from culture supernatants of BALB/c BMDCs maintained in medium with exosome-free FCS during the last 48 hours of culture. To promote DC maturation, in some experiments BALB/c BMDCs were incubated with IL-1β (20 ng/ml) and TNF-α (50 ng/ml) during the last 24 hours of culture. For isolation of MVs, BMDC (day 6) culture supernatants were centrifuged at 300 g (10 minutes), 1,200 g (20 minutes), and 10,000 g (30 minutes), all at 4°C. The 10,000-g pellets were collected, washed in PBS, and centrifuged at 10,000 g (30 minutes), and the final pellets were harvested in 200 μl of PBS.
T and B allosensitization, or other subsets of recipient APCs. This phenomenon may not be restricted to secondary lymphoid tissues but could also be operational in the graft where recipient APCs are cross-dressed and present donor MHC to recipient T cells (52) . These recipient APCs could activate memory T cells that infiltrate the graft -bypassing lymphoid tissues -or could return to the secondary lymphoid tissues to prime T cells. KO B6 mice were bred in our animal facility. Cytokines and Abs were purchased from PeproTech, and Abs from Abcam, BD Pharmingen, eBioscience, Invitrogen-Molecular Probes, Jackson ImmunoResearch Laboratories, Thermo Scientific, Santa Cruz Biotechnology, or Cedarlane. DT was purchased from Sigma-Aldrich. Heart and skin transplantation. Heterotopic (abdomen) vascularized cardiac transplantation was performed with the method of Corry et al. (53) . Palpation for heartbeat was conducted daily to determine organ survival. For the skin transplants, ears were removed from the donors and then split with forceps into dorsal and ventral halves. The dorsal halves, which contain no cartilage, were transplanted on beds prepared on the left and right lateral flanks of the recipient mice.
Methods
Estimation of donor cell number by quantitative PCR. DNA was extracted with TRIzol (Invitrogen) from spleens and mediastinal and retroperitoneal lymph nodes of B6 mice untreated or 1, 2, 3, or 7 days after they received BALB/c heart grafts. DNA was diluted in DNase/ RNase-free water (100 ng/μl), and BALB/c DNA was amplified and quantified by quantitative PCR with a StepOne thermal cycler (Applied Biosystems), using primers targeted to a region of the MHC class II IEα gene (H2-Eα) encoded in the BALB/c H2 d haplotype (GenBank K00971) and absent in the B6 genome. Primers were designed with the Invitrogen custom primer software Oligo Perfect Designer. H2-Eα forward 5′-AGAAAATGGCCACAATTGGA-3′ and reverse 5′-TCTGGGAGCTCATCAGAACA-3′ primers were from Invitrogen. DNA integrity and loading were normalized using the housekeeping gene S15 (forward primer 5′-GTGGAAGCTGGTGGATTCAT-3′ and reverse primer 5′-ACACCCAGAAAGGAACATGC-3′). Reactions were done in 50 μl of total volume with 1.2 μg of genomic DNA, which is equivalent to approximately 10 6 cells. Final concentration (200 mM) of each primer was mixed with 25 μl of 2× Fast SYBR Green Master Mix (Applied Biosystems). DNase-and RNase-free water was used to bring the reactions to a final volume of 50 μl. The quantitative PCR cycling conditions were as follows: initial hold for 20 seconds at 95°C, followed by 40 cycles of 95°C for 15 seconds (denaturing), and 60°C for 1 minute (annealing/extending). For standardization, BALB/c DNA was serially diluted into B6 DNA, resulting in BALB/c/B6 DNA ratios from 1:10 to 1 :10 6 . DNase/RNase-free water and DNA extracted from untreated naive B6 mice were used as controls. Normalization to control for DNA integrity and loading, and to compensate for inter-PCR variation, was performed with the Pfaffl method. The PCR-derived standard curve had a sensitivity of 1 BALB/c cell per 10 6 B6 splenocytes. 
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